OncoMyx Therapeutics

[On Demand]
OncoMyx Therapeutics is developing multi-armed, IV-delivered, and precision medicine oncolytic immunotherapies. The company has the industry’s most experienced oncolytic virus development team, CEO Steve Potts was previously at Ignyta (acquired by Roche for $1.7B), and Mirati CEO Chuck Baum is Chairperson. OncoMyx is seeking a $50M+ series B/crossover financing.
Cofounder, CEO & Director
OncoMyx Therapeutics